Basit öğe kaydını göster

dc.contributor.authorBalci-Hayta, Burcu
dc.contributor.authorTalim, Beril
dc.contributor.authorKale, Gulsev
dc.contributor.authorDincer, Pervin
dc.date.accessioned2019-12-12T06:25:13Z
dc.date.available2019-12-12T06:25:13Z
dc.date.issued2018
dc.identifier.issn1471-2377
dc.identifier.urihttps://doi.org/10.1186/s12883-018-1207-0
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295086/
dc.identifier.urihttp://hdl.handle.net/11655/16257
dc.description.abstractBackground Alpha-dystroglycan (αDG) is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin globular domains and certain arenaviruses. An important enzyme, known as Like-acetylglucosaminyltransferase (LARGE), has been shown to transfer repeating units of -glucuronic acid-β1,3-xylose-α1,3- (matriglycan) to αDG that is required for functional receptor as an extracellular matrix protein scaffold. The reduction in the amount of LARGE-dependent matriglycan result in heterogeneous forms of dystroglycanopathy that is associated with hypoglycosylation of αDG and a consequent lack of ligand-binding activity. Our aim was to investigate whether LARGE expression showed correlation with glycosylation of αDG and histopathological parameters in different types of muscular dystrophies, except for dystroglycanopathies. Methods The expression level of LARGE and glycosylation status of αDG were examined in skeletal muscle biopsies from 26 patients with various forms of muscular dystrophy [Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), sarcoglycanopathy, dysferlinopathy, calpainopathy, and merosin and collagen VI deficient congenital muscular dystrophies (CMDs)] and correlation of results with different histopathological features was investigated. Results Despite the fact that these diseases are not caused by defects of glycosyltransferases, decreased expression of LARGE was detected in many patient samples, partly correlating with the type of muscular dystrophy. Although immunolabelling of fully glycosylated αDG with VIA4–1 was reduced in dystrophinopathy patients, no significant relationship between reduction of LARGE expression and αDG hypoglycosylation was detected. Also, Merosin deficient CMD patients showed normal immunostaining with αDG despite severe reduction of LARGE expression. Conclusions Our data shows that it is not always possible to correlate LARGE expression and αDG glycosylation in different types of muscular dystrophies and suggests that there might be differences in αDG processing by LARGE which could be regulated under different pathological conditions.
dc.language.isoen
dc.relation.isversionof10.1186/s12883-018-1207-0
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleLarge Expression in Different Types of Muscular Dystrophies other than Dystroglycanopathy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalBMC Neurology
dc.contributor.departmentTıbbi Biyoloji
dc.identifier.volume18
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster